NCT04941599

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Vanderbilt University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.

Conditions

• Familial Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	2-Hydroxybenzylamine	2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
OTHER	Placebo	Placebo 250 mg three tabs TID (po) for 6 weeks.

Timeline

• Start date: 2024-02-14
• Primary completion: 2026-06-30
• Completion: 2026-12-31
• First posted: 2021-06-28
• Last updated: 2026-02-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study